View all news

    Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 31/2-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

    12/09/2017
    Download(opens in new window)PDF 488 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com